Genomic Classifier Improves Confidence in Interstitial Lung Disease Diagnosis
A new genomic classifier added to bronchoscopic lung cryobiopsy increased the diagnostic confidence of physicians for interstitial lung disease.
Restrictive Lung Disease
Anti-Acid Therapy Not Recommended in Systemic Sclerosis Interstitial Lung Disease
Researchers evaluated the effect of anti-acid treatment on disease progression in systemic sclerosis interstitial lung disease.
Lung Ultrasound B-Lines May Predict Pulmonary Deterioration in Systemic Sclerosis
Lung ultrasound B-lines can depict modifications in the lung parenchyma of patients with systemic sclerosis and may be an independent predictor of additional pulmonary deterioration in individuals with the disease.
Circulating mtDNA Is a Promising Biomarker in Idiopathic Pulmonary Fibrosis
An increase in circulating serum mitochondrial DNA is associated with worse survival in patients with newly diagnosed idiopathic pulmonary fibrosis.
BMI, Changes in Weight Linked to Mortality in Fibrotic Interstitial Lung Disease
Both body mass index and changes in weight have been linked to 1-year mortality risk in patients with fibrotic interstitial lung disease.
Computed Tomography Densitometry as a Marker of Disease Severity in SSc-ILD
Computed tomography densitometry may serve as an additional marker of disease severity in interstitial lung disease.
Homocitrullination May Be Linked to Interstitial Lung Disease in Rheumatoid Arthritis
A link between homocitrullination and the development of interstitial lung disease in patients with rheumatoid arthritis may exist.
Large Clinical Trial to Evaluate Ambulatory Oxygen Is Feasible in Interstitial Lung Disease
The results of a pilot study have demonstrated feasibility of conducting a large clinical trial in patients with fibrotic interstitial lung disease.
Ofev Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
Pirfenidone is currently marketed as Esbriet for the treatment of idiopathic pulmonary fibrosis in adults.
-
Loading...
-
Loading...
Next post in Restrictive Lung Disease
